Carl Zeiss Meditec AG Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 76 Fair Values set on narratives written by author
AFX Community Narratives
Digital And AI Advances Will Expand Global Eye Care Markets
VISUMAX 800 Approval In China Will Strengthen Future Market Position
Regulatory Uncertainty And Trade Tensions Will Depress Margins
Digital And AI Advances Will Expand Global Eye Care Markets
View narrativeVISUMAX 800 Approval In China Will Strengthen Future Market Position
View narrativeRegulatory Uncertainty And Trade Tensions Will Depress Margins
View narrativeTrending Discussion
No trending discussion available.
Recently Updated Narratives
AFX: Earnings Reset Risk From China Headwinds Will Shape Future Prospects
AFX: China And US Earnings Headwinds Will Constrain Medium Term Repricing
AFX: Reset Expectations And New Leadership Will Support Future Upside
Snowflake Analysis
Carl Zeiss Meditec AG Key Details
- 1.39
- 51.56%
- 5.57%
- 27.6%
About AFX
- Founded
- 1846
- Employees
- 5798
- CEO
- Website
View website
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company has a strategic collaboration with Envision Health Technologies Inc. to help advance glaucoma care through gamified virtual reality technology. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.